Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2313)	6/4/2010 11:58:36 AM
From: Jibacoa	Respond to of 3722

MATK is up for 2nd day on a roll and it opened with a good UG.<g> It has found recent support at the $18 level. The stock was up 18.75% and is still up 16.26% at present Volume of > 816Ks is about 3x its ADV bigcharts.marketwatch.com MATK reported its 2ndQ results yesterday,which beat earnings expectations and projected its full-year earnings would top forecasts.<g> Revenues were up 34% and earnings 36% to $0.45/shr.<g> Nutritional ingredient sales increased 14% to a record level of $99.7M The ACTAY is $26.29 Although MATK has a good amount of resistance from the $24 to the $25 level, with some further good news,it seems that the stock gould get to the $30 level.<g> bigcharts.marketwatch.com Bernard